Medical device producer NeoTract has agreed to be acquired by Teleflex for $1.1bn, giving an exit to Johnson & Johnson, a notable deal in a field where corporate commitments have been on the rise.

Led by McKesson Ventures, the money will support accelerated company growth.

Pfizer and Ipsen-backed Rhythm Pharmaceuticals has filed for an initial public offering on Nasdaq.

The university venture fund, backed by UZH Foundation and Novartis Venture Fund, has made its first investment in a University of Zurich spinout, Cutiss.

University of Minnesota has spun out CoreBiome, which will commercialise genomic and informatics technology aimed at the agricultural, environmental and healthcare sectors.

Entasis, which previously raised $50m in a Novo and AstraZeneca-backed series B last year, has added $31.9m in series B-1 round.

The corporate-backed genetic testing company is targeting a $200m funding round led by Sequoia Capital.

Teleflex is set to acquire Johnson & Johnson-backed NeoTract for a total of $1.1bn, with $725m to be paid upfront and the remainder dependent on certain milestones.